Clinical Trial Update: Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of capecitabine given on a 7/7 schedule in combination with neratinib for metastatic HER2-positive breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• neratinib (neratinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING